国产替罗非班治疗高危急性冠脉综合征的临床观察

Clinical application of tirofiban in patients with high-risk acute coronary artery syndrome

目的观察国产替罗非班在急性冠脉综合征(ACS)高危组药物治疗中的临床效果。方法符合不稳定型心绞痛(UA)、急性心肌梗死(AMI)危险度分层高危组的患者83例,根据是否应用替罗非班分为治疗组(51例)和对照组(32例)。观察2组住院期间及出院后共30d内发生的心血管事件(MACE),包括心血管性死亡,新出现的心肌梗死、脑卒中、顽固缺血状态伴ST-T改变,出血并发症及血小板减少情况。结果与对照组相比,治疗组住院期间所观察心血管事件发生率有所降低(15.7%比18.8%,P<0.05)。两组严重出血发生率差异无统计学意义。治疗组轻度出血比对照组有所增加,但差异无统计学意义(P>0.05)。结论国产替罗非班在高危ACS治疗中可减少30d内心血管事件,出血事件无明显增加。

Objective To observe the clinical effect and safety of tirofiban in patient with high-risk acute coronary artery syndrome （ACS） without PCI therapy. Methods The present study registered 83 high-risk ACS patients who were divided into the tirofiban group （n=51） who received tirofiban and conventional therapy and the control group（n=32 ） who received conventional therapy.The major adverse cardiac （MACE） include refractory ische mia, new myocardial infarction and death, cerebral apoplexy and hemorrhage complication were observed. Results The MACE at 30 days was significantly lower in the tirofiban group than in the placebo group （15.7% vs 18.8%, P〈0.05 ）.There were no differences in the incidence of bleeding or platelet decrease between two groups.Conclusions Tirofiban may further lower the incidence of MACE in treating high-risk ACS patients on the basis of conventional treatment in the recent 30 days, and hemorrhage complications do not increase.